For business development
Know what the asset is worth before the data room opens.
In-licensing, out-licensing or partnering: get an independent, cited read on the asset — the comparable-trial record, the patent runway, the enrolment reality and a risk-adjusted valuation whose inputs are all visible — from public data alone.
One independent number, visible to both sides.
The situation
Both sides are arguing from the same deck.
A partnering conversation starts with the seller’s narrative. The buy side needs an independent view fast enough to be useful in the first meeting — and specific enough to survive the second one.
- Live public sources behind the read
- ~50
- Public evidence is enough to start
- No data room
- The same read, re-derived as the asset moves
- Re-runnable
What happens today
The counter-view arrives after the term sheet.
Screening a partnering opportunity properly costs weeks of specialist time, so most opportunities get a shallow look and a small number get a deep one — usually after the deal already has momentum.
The narrative sets the anchor
The first number in the room comes from the seller’s model, built on the seller’s timeline. Everything after that is negotiation against an anchor nobody independently checked.
Deep diligence is too slow to screen with
A proper read takes weeks of scientific and commercial time. That is affordable for the deal you are already doing, not for the twenty you are choosing between.
Patent runway is assumed, not measured
Exclusivity remaining at the expected readout is the variable most likely to change a valuation — and the one most often carried forward from the target’s own summary.
Execution risk sits outside the model
Whether the pivotal trial can actually enrol on the stated timeline determines the value more than the discount rate does, and it rarely appears as a line in the model.
What you get instead
An independent read on the asset in front of you.
A directional probability of success
Grounded in published base rates for the phase and area, adjusted for what the assessment found about this specific program — with every adjustment shown, so the counterparty can argue with the inputs.
Risk-adjusted valuation you can re-run
Market sizing, value-based price against the standard of care, and an eNPV whose drivers are all exposed for your own model.
Patent and exclusivity runway
The patent landscape around the molecule and its class, and how much exclusivity remains when the trial is expected to read out.
The comparable-trial record
What has already been tried in this indication, what happened, and the stated reasons the failures failed — the base rate behind the pitch.
Whether the pivotal can enrol
Cohort reach, eligibility burden and competing-trial density against the timeline the target is guiding to.
Screen the pipeline, not one asset
Run every opportunity on the same six pillars so the shortlist is a ranking on comparable evidence rather than a ranking on who pitched best.
What runs, and who drafts
The scope for this job
A deal is decided on the science, the commercial case and whether the pivotal is runnable. Where & How runs as the execution check on the target’s timeline rather than as an operational plan you will own.
Pillars involved
How it runs
From an asset name to a position.
Name the asset
A molecule or drug class and an indication is enough. Nothing confidential has to change hands, so you can run this before a CDA rather than after one.
The assessment builds the counter-view
Six pillars, more than 30 analyses, around 50 live public sources — the scientific case, the design, the enrolment reality, the patent runway and the valuation, all cited.
Take a position, then re-run it
Go into the room with an independent read. As the program moves — a readout, a filing, a competitor entering — re-run it and see precisely what changed.
What lands on your desk
A position paper with visible inputs.
Structured so the counterparty can disagree with a specific assumption rather than with the conclusion — which is the only kind of disagreement that moves a deal.
What lands on your desk
Asset assessment + valuation input pack
- A directional probability of success with its base rate and every adjustment listed separately.
- Risk-adjusted valuation with market size, value-based price and standard of care as replaceable inputs.
- Patent and exclusivity runway measured against the expected readout date.
- The comparable-trial record for the indication, including trials that stopped and their stated reasons.
- An enrolment feasibility check against the timeline the target is guiding to.
- Full citations with snapshot dates, and a reproducible run you can re-derive later.
Honest limits
Where this stops
What this does not do for you. Naming it here is cheaper for both of us than finding it in a procurement review.
It is an evidence synthesis from public data — not investment or legal advice, and not a substitute for confirmatory diligence once the data room opens.
Patent analysis reads public patent and exclusivity records. It is not a freedom-to-operate opinion and does not replace patent counsel.
Valuation outputs are inputs for your model. Every driver is exposed precisely so that you replace the ones you disagree with.
Public data only: unpublished preclinical results, confidential regulatory correspondence and undisclosed competitor programs are invisible to it.
The probability of success is directional, presented with its assumptions — not a forecast and not a number to put in a term sheet unqualified.
Questions
The ones you would ask first
Can we run this before a CDA is in place?
Yes. The assessment uses public sources only, so naming a molecule or drug class and an indication is enough. Nothing confidential has to change hands to get a read.
How does this fit alongside our banker or our diligence advisors?
It gives them a cited evidence base to work from instead of starting at the search bar, and gives you an independent anchor before the first number is put on the table.
Is the patent analysis a freedom-to-operate opinion?
No. It reads public patent and exclusivity records to establish the runway around the asset and its class. Freedom to operate is a legal opinion and requires patent counsel.
Can we screen a whole pipeline of opportunities?
Yes. Every asset is run through the same six pillars, so a shortlist is a ranking on comparable evidence rather than a ranking on how each one was presented.
Walk in with your own number.
Name the asset and the indication. We’ll return an independent, fully cited read — valuation inputs, patent runway, comparable-trial record and enrolment reality — before the data room opens.